Summit Therapeutics Inc. (SMMT) BTC Phase III Data Slated for ESMO; Topline Showed OS Superiority
Summit said Akeso’s Phase III HARMONi-GI1 trial of ivonescimab plus chemo vs durvalumab plus chemo will be presented at ESMO 2026. Akeso previously reported interim OS superiority and PFS/ORR wins.Material DetailsContext by AI AnalystThis is mid-cycle validation of ivonescimab’s profile, adding to…